Weight Loss

Retatrutide

89,99 €

CAS 2381275-14-3
SKU RETA-10MG
For in vitro research use only. Not for human or animal consumption.

Overview

Retatrutide (LY3437943) is a synthetic peptide engineered to simultaneously agonise three key metabolic receptors: glucose-dependent insulinotropic polypeptide receptor (GIPR), glucagon-like peptide-1 receptor (GLP-1R), and glucagon receptor (GCGR). This triple receptor engagement represents one of the most advanced incretin research pharmacology profiles currently studied.

Key Research Areas

  • Triple Incretin Receptor Agonism: Simultaneous engagement of GIP-R, GLP-1R, and GCGR modulates complementary and synergistic pathways in energy homeostasis – a more comprehensive metabolic signalling profile than single or dual agonists.
  • Adipose Tissue Research: Phase 2 clinical data published in the NEJM (2023) demonstrated substantial body weight reduction, making it a central compound in obesity mechanism research.
  • Glucose Homeostasis: GLP-1 and GIP components contribute to glucose-dependent insulin secretion; the glucagon component adds hepatic glucose output modulation.
  • Hepatic Research: GCGR agonism studied for its role in NAFLD/NASH models through hepatic lipid oxidation and gluconeogenesis modulation.
  • Thermogenesis Models: Glucagon component investigated for brown adipose tissue activation and increased basal metabolic rate.

Specifications

  • CAS: 2381275-14-3
  • Molecular Weight: ~4800 g/mol
  • Purity: ≥99% (HPLC verified)
  • Form: Lyophilised powder, 10 mg per vial

For in vitro laboratory research use only. Not for human or animal administration.